surmount tirzepatide trials SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, tirzepatide trials SURMOUNT-1 Trial A

VAS = visual analogue scale

Sulfur burps tend to peak in the early weeks of GLP-1 treatment or after a dose increase, and then gradually subside as the body adjusts

Appetite Suppression: By slowing gastric emptying and reducing appetite, GLP-1 peptides make it easier to adhere to a calorie-controlled diet

Discontinuation due to adverse events was 4.3-7.1% across tirzepatide doses versus 2.6% placebo

PlexusDx supplies only semaglutide and tirzepatide within the GLP-1 category, via its Weight Management Protocols, and does not sell, prescribe, or recommend dulaglutide, liraglutide, cagrilintide, or retatrutide

10.1002/cncr.28744 71 PinnickK